Background: Prohibitin (PHB) is a multifunctional protein that is localized in different intracellular sites. PHB may exert different roles in tumorigenesis, having either a permissive action on tumor growth or an oncosuppressor role, depending on the cellular context. The objective of this study was to evaluate PHB expression in normal thyroid tissues, thyroid follicular adenomas (FAs), and papillary thyroid carcinomas (PTCs). Methods: PHB expression was analyzed by immunohistochemistry, Western blot, and quantitative reverse transcription polymerase chain reaction (RT-PCR). Transfections in the BCPAP and TPC-1 thyroid cancer cell lines were used to evaluate the PHB promoter activity. Results: In terms of protein and mRNA levels, normal tissues from patients with serum thyrotropin (TSH) values >0.8 mU/L had PHB levels that were significantly reduced compared to specimens from patients with serum TSH values <0.5 mU/L, suggesting that TSH exerts an inhibitory effect on PHB expression. Consistent with this was the finding that the presence of TSH was associated with low PHB levels in normal FRTL5 thyroid cells. Immunohistochemical analysis showed relatively low and high PHB expression in FAs and PTCs, respectively. PHB mRNA and protein overexpression, as assessed by quantitative RT-PCR and Western blot, was noted only in PTCs bearing the BRAFV600E mutation. Notably, cell transfection experiments suggested that presence of the BRAFV600E mutation may be associated to increase of the PHB promoter activity. Conclusions: PHB is overexpressed in PTCs bearing the BRAFV600E mutation. We postulate that the presence of the BRAFV600E mutation increases PHB promoter activity and therefore potentially mediates effects of this mutation on the behavior of BRAF V600E positive PTCs. © Copyright 2009, Mary Ann Liebert, Inc.

Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAFV600E mutation / Alessandra, Franzoni; Dima, Mariavittoria; Maria, D'Agostino; Cinzia, Puppin; Dora, Fabbro; Loreto, Cd; Maura, Pandolfi; Efisio, Puxeddu; Sonia, Moretti; Marilena, Celano; Rocco, Bruno; Filetti, Sebastiano; Diego, Russo; Giuseppe, Damante. - In: THYROID. - ISSN 1050-7256. - 19:3(2009), pp. 247-255. [10.1089/thy.2008.0235]

Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAFV600E mutation

DIMA, MARIAVITTORIA;FILETTI, SEBASTIANO;
2009

Abstract

Background: Prohibitin (PHB) is a multifunctional protein that is localized in different intracellular sites. PHB may exert different roles in tumorigenesis, having either a permissive action on tumor growth or an oncosuppressor role, depending on the cellular context. The objective of this study was to evaluate PHB expression in normal thyroid tissues, thyroid follicular adenomas (FAs), and papillary thyroid carcinomas (PTCs). Methods: PHB expression was analyzed by immunohistochemistry, Western blot, and quantitative reverse transcription polymerase chain reaction (RT-PCR). Transfections in the BCPAP and TPC-1 thyroid cancer cell lines were used to evaluate the PHB promoter activity. Results: In terms of protein and mRNA levels, normal tissues from patients with serum thyrotropin (TSH) values >0.8 mU/L had PHB levels that were significantly reduced compared to specimens from patients with serum TSH values <0.5 mU/L, suggesting that TSH exerts an inhibitory effect on PHB expression. Consistent with this was the finding that the presence of TSH was associated with low PHB levels in normal FRTL5 thyroid cells. Immunohistochemical analysis showed relatively low and high PHB expression in FAs and PTCs, respectively. PHB mRNA and protein overexpression, as assessed by quantitative RT-PCR and Western blot, was noted only in PTCs bearing the BRAFV600E mutation. Notably, cell transfection experiments suggested that presence of the BRAFV600E mutation may be associated to increase of the PHB promoter activity. Conclusions: PHB is overexpressed in PTCs bearing the BRAFV600E mutation. We postulate that the presence of the BRAFV600E mutation increases PHB promoter activity and therefore potentially mediates effects of this mutation on the behavior of BRAF V600E positive PTCs. © Copyright 2009, Mary Ann Liebert, Inc.
2009
01 Pubblicazione su rivista::01a Articolo in rivista
Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAFV600E mutation / Alessandra, Franzoni; Dima, Mariavittoria; Maria, D'Agostino; Cinzia, Puppin; Dora, Fabbro; Loreto, Cd; Maura, Pandolfi; Efisio, Puxeddu; Sonia, Moretti; Marilena, Celano; Rocco, Bruno; Filetti, Sebastiano; Diego, Russo; Giuseppe, Damante. - In: THYROID. - ISSN 1050-7256. - 19:3(2009), pp. 247-255. [10.1089/thy.2008.0235]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/95961
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 28
social impact